In addition, obesity leads to hyperactivation of the mTOR pathway in epithelial tissues, suggesting that mTOR inhibitors may be a logical choice for treatment in obesity-driven cancers. Here, MTOR is linked to obesity due to melanocortin 4 receptor deficiency.